My Blue Dots

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025. “With our team’s innovation and execution throughout 2024, Rallybio is well positioned to create meaningful value in 2025,” said Stephen Uden, M.D., Chief Executive Officer of Rallybi

ST. LOUIS–(BUSINESS WIRE)–Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board Member to lead Cofactor’s plan to bring precision medicine to immunotherapy. Simultaneously, the company announced that Jarret Glasscock, scientist and Cofactor Genomics founder, will transition into the role of President, Chief Technology Officer (CTO), and Board Member. Parker j

SAN DIEGO–(BUSINESS WIRE)–Element Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine. In this groundbreaking study funded by Cancer Research UK, co-authors Black and Bartha et al. highlight advancements in lung cancer detection using NeXT Personal®, an ultra-sensitive personalized test designed to detect

BELOIT, Wis. & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for Development and Production of Radiopharmaceutical Products

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. The Company is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. Verdiva launches with an oversubscribed Series A financing of $411M, co-led by Forbion and General Atlantic,

HOUSTON–(BUSINESS WIRE)–SynergenX Health and HerKare, two leading providers of hormone therapy and wellness services, are raising awareness about the life-changing benefits of testosterone replacement therapy (TRT) for women. Over the past decade, testosterone prescriptions have increased by almost 50% in the United States alone. Testosterone, often associated with men, is vital for women’s health, playing a key role in energy, mood, libido, and muscle maintenance. As women age, testosterone

MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case transmission featuring the nsPFA 360° catheter mapped with the Abbott Ensite X 3D Mapping System at the 30th Annual AF Symposium 2025 meeting, being held January 16-18 in Boston, Massachusetts. “Since joining the Company’s

AUSTIN, Texas–(BUSINESS WIRE)– #JPM2025–Gameto to Present at 43rd Annual J.P. Morgan Healthcare Conference